Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy : a Randomized, Multicenter, Open-label Phase III Study

NCT05111197 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT05111197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05111197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy : a Randomized, Multicenter, Open-label Phase III Study
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Phase 3
Overall status
Unknown status
Start date
January 12, 2022
Completion date
January 31, 2025
Enrollment
112 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced non small cell lung cancer, metastatic non small cell lung cancer